In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. Ubiquitin-relevant proteins that regulate the stability of important Tremendous enhancer-mediated proteins have also https://davidy221mzk5.birderswiki.com/user